Voluntary health agency jump-starts Selvit... The Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients … more ➔
LEO orders Hitgen to discover new leads In a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist. more ➔
Vernalis receives next veto by FDA British biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08. more ➔
Hansas immunomodulatory enzyme does the... Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection. more ➔
TC Biopharm gets €4m Horizon2020 grantThe Scottish biotech company TC Biopharm (TCB) has been awarded a €4m grant from the European Unions Horizon 2020 programme. more ➔
Zealand taps US marketDanish diabetes biotech Zealand Pharma has started its initial public offering in the US at Nasdaq Global Select Market. It plans to raise US$75m to fund clinical trails. more ➔
Uniqure from now on aloneItalian pharma company Chiesi Farmaceutici withdraws from a co-development agreement with gene therapy pioneer Uniqure. This will add US$1.5m to Uniqures expenses this year. more ➔
Neovacs raises €6m through private place...French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares. more ➔
J&J intensifies vaccine endeavour wit... Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV. more ➔
GSK cancels 30 preclinical and clinical pr... UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious … more ➔
